Avalo Therapeutics, Inc. (AVTX)

Market Cap	12.68M
Revenue (ttm)	1.45M
Net Income (ttm)	-142.88M
Shares Out	1.03M
EPS (ttm)	-192.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,201
Open	12.30
Previous Close	12.05
Day's Range	12.09 - 12.98
52-Week Range	3.95 - 95.52
Beta	1.14
Analysts	Buy
Price Target	107.50 (+776.84%)
Earnings Date	Aug 1, 2024

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory dis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX

Financial Performance

In 2023, AVTX's revenue was $1.92 million, a decrease of -89.34% compared to the previous year's $18.05 million. Losses were -$31.54 million, -24.28% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AVTX stock is "Buy." The 12-month stock price forecast is $107.5, which is an increase of 776.84% from the latest price.

Price Target

$107.5

(776.84% upside)

Analyst Consensus: Buy